Insider Selling: Seagen Inc. (NASDAQ:SGEN) Director Sells $108,800.00 in Stock

Seagen Inc. (NASDAQ:SGEN – Get Rating) Director Daniel G. Welch sold 544 shares of the company’s stock in a transaction that occurred on Tuesday, March 14th. The shares were sold at an average price of $200.00, for a total value of $108,800.00. Following the completion of the sale, the director now owns 12,977 shares of the company’s stock, valued at $2,595,400. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Seagen Trading Down 0.1 %

Shares of NASDAQ SGEN opened at $200.30 on Friday. Seagen Inc. has a 12-month low of $105.43 and a 12-month high of $202.86. The business’s fifty day simple moving average is $153.97 and its 200-day simple moving average is $140.38.

Seagen (NASDAQ:SGEN – Get Rating) last announced its quarterly earnings data on Wednesday, February 15th. The biotechnology company reported ($0.80) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.02) by $0.22. The business had revenue of $528.20 million for the quarter, compared to analysts’ expectations of $479.81 million. Seagen had a negative return on equity of 21.13% and a negative net margin of 31.10%. The company’s revenue for the quarter was up 22.9% compared to the same quarter last year. During the same period last year, the firm earned ($0.95) earnings per share. On average, research analysts forecast that Seagen Inc. will post -2.98 earnings per share for the current fiscal year.

Institutional Trading of Seagen

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. raised its stake in Seagen by 1.4% in the third quarter. Vanguard Group Inc. now owns 12,663,152 shares of the biotechnology company’s stock valued at $1,732,699,000 after buying an additional 170,001 shares in the last quarter. BlackRock Inc. raised its stake in Seagen by 3.5% in the third quarter. BlackRock Inc. now owns 11,826,822 shares of the biotechnology company’s stock valued at $1,618,264,000 after buying an additional 394,562 shares in the last quarter. State Street Corp raised its stake in Seagen by 0.7% in the first quarter. State Street Corp now owns 3,525,411 shares of the biotechnology company’s stock valued at $507,835,000 after buying an additional 24,853 shares in the last quarter. JPMorgan Chase & Co. raised its stake in Seagen by 12.5% in the fourth quarter. JPMorgan Chase & Co. now owns 3,272,789 shares of the biotechnology company’s stock valued at $420,584,000 after buying an additional 363,133 shares in the last quarter. Finally, FMR LLC raised its stake in Seagen by 17.9% in the second quarter. FMR LLC now owns 2,671,697 shares of the biotechnology company’s stock valued at $472,730,000 after buying an additional 405,593 shares in the last quarter. 86.25% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

SGEN has been the subject of several analyst reports. JPMorgan Chase & Co. lowered their price objective on Seagen from $154.00 to $150.00 and set an “overweight” rating for the company in a research report on Monday, February 13th. Royal Bank of Canada increased their price objective on Seagen from $155.00 to $229.00 and gave the stock an “outperform” rating in a research report on Tuesday, March 14th. TheStreet upgraded Seagen from a “d+” rating to a “c-” rating in a research report on Wednesday, February 22nd. Morgan Stanley lowered Seagen from an “overweight” rating to an “equal weight” rating and increased their price objective for the stock from $173.00 to $229.00 in a research report on Wednesday. Finally, Truist Financial increased their price objective on Seagen from $135.00 to $152.00 in a research report on Friday, February 17th. Ten investment analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $187.29.

Seagen Company Profile

(Get Rating)

Seagen Inc is a biotechnology company, which engages in the development and commercialization of targeted therapies for the treatment of cancer. It also engages in the advancement of therapies for solid tumors and blood-related cancers. Its products include Adcetris, Padcev, Tivdak, and Tukysa. The company was founded by Clay B.